SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/10/15 Unitedhealth Group Inc 10-K 12/31/14 111:26M |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.49M 2: EX-10.2 Material Contract HTML 35K 3: EX-10.3 Material Contract HTML 83K 4: EX-10.32 Material Contract HTML 57K 6: EX-21.1 Subsidiaries List HTML 128K 7: EX-23.1 Consent of Experts or Counsel HTML 34K 8: EX-24.1 Power of Attorney HTML 40K 5: EX-12.1 Statement re: Computation of Ratios HTML 45K 9: EX-31.1 Certification -- §302 - SOA'02 HTML 48K 10: EX-32.1 Certification -- §906 - SOA'02 HTML 36K 76: R1 Document and Entity Information Document HTML 63K 62: R2 Consolidated Balance Sheets HTML 152K 73: R3 Consolidated Balance Sheet (Parenthetical) HTML 68K 80: R4 Consolidated Statements of Operations HTML 123K 101: R5 Consolidated Statements of Comprehensive Income HTML 82K 64: R6 Consolidated Statements of Changes in HTML 113K Shareholders' Equity 72: R7 Consolidated Statements of Cash Flows HTML 162K 55: R8 Description of Business (Notes) HTML 33K 45: R9 Basis of Presentation, Uses of Estimates and HTML 128K Significant Accounting Policies (Notes) 103: R10 Investments (Notes) HTML 297K 82: R11 Fair Value (Notes) HTML 336K 81: R12 Property, Plant, and Capitalized Software (Notes) HTML 55K 88: R13 Goodwill and Intangible Assets (Notes) HTML 120K 89: R14 Medical Cost Reserve Development and Medical Costs HTML 61K Payable (Notes) 86: R15 Commercial Paper and Long-Term Debt (Notes) HTML 222K 90: R16 Income Taxes (Notes) HTML 155K 74: R17 Shareholders' Equity (Notes) HTML 57K 77: R18 Share-Based Compensation (Notes) HTML 115K 84: R19 Commitments and Contingencies (Notes) HTML 58K 111: R20 Segment Financial Information (Notes) HTML 317K 97: R21 Quarterly Financial Data (Unaudited) (Notes) HTML 85K 68: R22 Schedule I (Notes) HTML 191K 83: R23 Basis of Presentation, Uses of Estimates and HTML 195K Significant Accounting Policies (Policies) 70: R24 Fair Value Fair Value (Policies) HTML 48K 36: R25 Basis of Presentation, Uses of Estimates and HTML 88K Significant Accounting Policies (Tables) 98: R26 Investments (Tables) HTML 300K 107: R27 Fair Value (Tables) HTML 329K 50: R28 Property, Plant, and Capitalized Software (Tables) HTML 53K 49: R29 Goodwill and Intangible Assets (Tables) HTML 123K 53: R30 Medical Cost Reserve Development and Medical Costs HTML 62K Payable (Tables) 54: R31 Commercial Paper and Long-Term Debt (Tables) HTML 226K 57: R32 Income Taxes (Tables) HTML 177K 25: R33 Shareholders' Equity (Tables) HTML 41K 95: R34 Share-Based Compensation (Tables) HTML 115K 66: R35 Commitments and Contingencies Commitments and HTML 43K Contingencies (Tables) 69: R36 Segment Financial Information (Tables) HTML 302K 40: R37 Quarterly Financial Data (Unaudited) (Tables) HTML 84K 110: R38 Schedule I (Tables) HTML 197K 17: R39 Basis of Presentation, Uses of Estimates and HTML 84K Significant Accounting Policies (Details) 59: R40 Basis of Presentation, Uses of Estimates and HTML 46K Significant Accounting Policies Medicare Part D (Details) 100: R41 Basis of Presentation, Uses of Estimates and HTML 45K Significant Accounting Policies Useful lives for property, equipment and capitalized software (Details) 38: R42 Basis of Presentation, Uses of Estimates and HTML 53K Significant Accounting Policies Redeemable Noncontrolling Interests (Details) 48: R43 Investments (Narrative) (Details) HTML 36K 52: R44 Investments (Short-Term and Long-Term Investments) HTML 137K (Details) 63: R45 Investments (Fair Value of Mortgage-Backed HTML 114K Securities by Credit Rating Origination) (Details) 24: R46 Investments (Amortized Cost and Fair Value of HTML 87K Available-for-Sale Debt Securities by Contractual Maturity) (Details) 44: R47 Investments (Amortized Cost and Fair Value of HTML 66K Held-To-Maturity Debt Securities by Contractual Maturity) (Details) 19: R48 Investments (Fair Value of Available-For-Sale HTML 117K Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) 99: R49 Investments (Net Realized Gains) (Details) HTML 72K 37: R50 Fair Value (Narrative) (Details) HTML 61K 96: R51 Fair Value (Financial Assets and Liabilities, HTML 145K Excluding AARP, Measured at Fair Value on a Recurring Basis) (Details) 41: R52 Fair Value (Financial Assets and Liabilities, HTML 127K Excluding AARP, Not Measured at Fair Value on a Recurring Basis) (Details) 60: R53 Fair Value (Reconciliation of Assets Measured at HTML 98K Fair Value on a Recurring Basis Using Level 3 Inputs) (Details) 18: R54 Fair Value Fair Value Inputs Assets Quantitative HTML 52K Information (Details) 22: R55 Fair Value (Assets and Liabilities measured at HTML 189K fair value on a recurring basis) (Details) 51: R56 Property, Plant, and Capitalized Software HTML 38K (Details) 29: R57 Property, Plant, and Capitalized Software Property HTML 62K Plant and Equipment Table (Details) 104: R58 Goodwill and Intangible Assets (Details) HTML 36K 65: R59 Goodwill and Intangible Assets Changes in the HTML 64K Carrying Amount of Goodwill by Reporting Segment (Details) 87: R60 Goodwill and Intangible Assets Gross carrying HTML 63K value, accumulated amortization and net carrying value of intangible assets (Details) 43: R61 Goodwill and Intangible Assets Weighted-average HTML 48K useful lives assigned to finite-lived intangible assets acquired in business combinations (Details) 46: R62 Goodwill and Intangible Assets Amortization HTML 45K Expense relating to Intangible Assets (Details) 94: R63 Medical Costs and Medical Costs Payable HTML 58K Rollforward (Details) 91: R64 Commercial Paper and Long-Term Debt (Narrative) HTML 73K (Details) 67: R65 Commercial Paper and Long-Term Debt (Details) HTML 271K 93: R66 Commercial Paper and Long-Term Debt Maturities of HTML 51K commercial paper and long-term debt (Details) 42: R67 Commercial Paper and Long-Term Debt Fair Value HTML 46K Hedges Statement of Financial Position Location (Details) 71: R68 Commercial Paper and Long-Term Debt Fair Value HTML 48K Hedges Effect of Changes in Fair Value Hedges on Income (Details) 106: R69 Income Taxes (Details) HTML 64K 21: R70 Income Taxes Reconciliation of Provision for HTML 54K Income Taxes (Details) 35: R71 Income Tax Reconciliation of the tax provision at HTML 84K the U.S. Federal Statutory Rate (Details) 61: R72 Income Taxes Components of Deferred Tax Assets and HTML 102K Liabilities (Details) 27: R73 Income Taxes Reconciliation of the beginning and HTML 53K ending amount of unrecognized tax benefits (Details) 109: R74 Shareholders' Equity (Details) HTML 70K 39: R75 Shareholders' Equity Dividends Paid (Details) HTML 38K 30: R76 Share-Based Compensation Narrative (Details) HTML 44K 34: R77 Share-Based Compensation (Stock Option and SAR HTML 86K Activity) (Details) 23: R78 Share-Based Compensation (Restricted Share HTML 53K Activity) (Details) 26: R79 Share-Based Compensation Other Share-Based HTML 75K Compensation Data (Details) 78: R80 Share-Based Compensation (Share-Based Compensation HTML 64K Principal Fair Value Assumptions) (Details) 32: R81 Commitments and Contingencies (Details) HTML 70K 105: R82 Commitments and Contingencies Future Lease HTML 50K Payments (Details) 58: R83 Segment Financial Information (Narrative) HTML 49K (Details) 85: R84 Segment Financial Information (Details) HTML 261K 92: R85 Quarterly Financial Data (Unaudited) (Details) HTML 87K 31: R86 Schedule I (Details) HTML 65K 33: R87 Schedule I Condensed Balance Sheets (Details) HTML 132K 102: R88 Schedule I Balance Sheet Document (Details) HTML 64K 28: R89 Schedule I Condensed Statement of Comprehensive HTML 88K Income (Details) 79: R90 Schedule I Statement of Cash Flows (Details) HTML 127K 75: R91 Schedule I Maturities of Commercial Paper and HTML 56K Long-Term Debt (Details) 108: XML IDEA XML File -- Filing Summary XML 169K 20: EXCEL IDEA Workbook of Financial Reports XLSX 447K 47: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 4.36M 11: EX-101.INS XBRL Instance -- unh-20141231 XML 6.68M 13: EX-101.CAL XBRL Calculations -- unh-20141231_cal XML 313K 14: EX-101.DEF XBRL Definitions -- unh-20141231_def XML 1.53M 15: EX-101.LAB XBRL Labels -- unh-20141231_lab XML 2.64M 16: EX-101.PRE XBRL Presentations -- unh-20141231_pre XML 1.75M 12: EX-101.SCH XBRL Schema -- unh-20141231 XSD 252K 56: ZIP XBRL Zipped Folder -- 0000731766-15-000007-xbrl Zip 458K
UNH EX 31.1 12.31.2014 |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the
registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Chief Executive Officer | |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the
registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
President and Chief Financial Officer |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/10/15 | 3, 4, 8-K | ||
For Period end: | 12/31/14 | 11-K, ARS | ||
List all Filings |